This study aimed to investigate the efficacy and safety of Carrimycin tablets in hemophagocytic lymphohistiocytosis patients with Carbapenem-resistant infections.

Hemophagocytic lymphohistiocytosis (HLH) is a critical condition characterized by the undue activation of cytotoxic T lymphocytes, natural killer cells, and macrophages, resulting in excessive secretion of infammatory cytokines. Infection is an important trigger for HLH. This study aimed to investigate the efficacy and safety of Carrimycin tablets in hemophagocytic lymphohistiocytosis patients with Carbapenem-resistant infections.

Inclusion Criteria:

• Met HLH-2004 diagnostic criteria;
• Active infection；
• Empirical treatment with carbapenems did not respond after 72 hours；
• Age >18 years old, no gender limitation;
• Ability and willingness to adhere to the study visit schedule and all protocol requirements.

Exclusion Criteria:

• Other antibiotics should be selected according to the results of drug sensitivity；
• Systemic antibiotics other than carbapenems are used with 72 hours；
• Inability to take oral medications due to disease of gastrointestinal tract；
• Severe liver insufficiency;
• Expected survival time < 1 month;
• Pregnant or breasting-feeding women;
• Allergic to Carrimycin tablets;
• Active hepatitis B or hepatitis C infection;
• Patients with HIV infection;
• Patients with other contraindications considered unsuitable for participation in this study.